FDA Warns of Possible Dosing Errors in Compounded Injectables

News
Article

The agency announced that differences in strength expression on product labels of compounders and conventional manufacturers may lead to dosing errors.

On Sept. 27, 2018, FDA announced that it had received MedWatch reports of dosing errors and confusion with the labeled strength expression for certain compounded injectable products. The confusion, the agency states, is arising because “conventional manufacturers label their injectable products with the strength per total volume as the primary and prominent expression of strength on the label, whereas some compounders label their injectable products differently.”

The agency also has received complaints that the font size on the labeling may also cause confusion. “Displaying the strength per milliliter in larger, more prominent font, instead of the strength per total volume, may lead to confusion about how much drug is in the container.”

The agency stated that labeling compounded injectables using the same strength convention used by conventional manufacturers may reduce the risk of medication errors. “Because labels of compounded products are not reviewed by FDA prior to marketing, healthcare professionals should be vigilant when administering compounded products to patients to avoid confusion and ensure that each patient is administered the prescribed dose of the intended drug,” the agency stated on its website.

Source: FDA

 

Recent Videos
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.